SNDX — Syndax Pharmaceuticals Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1395937 ·
Last close
$18.20
Market Cap
$1.63B
52W High
$25.59
52W Low
$12.99
ADV30
1,579,223
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 72,788,000 | 69,580,000 | -39,995,000 | -49,363,000 | 703,652,000 | 336,477,000 | 688,553,000 |
| Mar 2026 | 64,864,000 | 62,231,000 | -34,202,000 | -42,673,000 | 472,668,000 | 130,893,000 | 431,046,000 |
| Dec 2025 | 68,728,000 | 66,022,000 | -62,548,000 | -68,014,000 | 529,706,000 | 134,930,000 | 465,076,000 |
| Sep 2025 | 45,871,000 | 43,771,000 | -57,426,000 | -60,715,000 | 551,792,000 | 116,808,000 | 436,362,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-220,640,000
Investing CF
$175,483,000
Financing CF
$272,883,000
CapEx
$-56,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.51
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,598,616,000
Inventory
$33,164,000
Receivables
$72,785,000
ST Investments
$217,789,000
EBIT TTM
$-178,367,000
Pretax Income TTM
$-220,765,000
Interest Exp TTM
$42,398,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$252,251,008
EBITDA
$-194,160,000
Free Cash Flow
$-150,078,624
Enterprise Value
$1,658,536,960
Total Cash
$554,265,984
Total Debt
$589,382,016
Shares Out
89,297,086
Trailing EPS
$-2.51
Book Value
$0.17
ROE
-255.9%
ROA
-18.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 172,352,000 | -273,084,000 | -285,422,000 | 529,706,000 | 465,076,000 | 64,630,000 | -322,980,000 |
| Dec 2024 | 23,680,000 | -339,672,000 | -318,758,000 | 724,816,000 | 436,692,000 | 288,124,000 | -274,903,000 |
| Dec 2023 | 0 | -229,954,000 | -209,360,000 | 612,880,000 | 58,684,000 | 554,196,000 | -160,601,000 |
| Dec 2022 | 0 | -151,757,000 | -149,338,000 | 497,236,000 | 29,787,000 | 467,449,000 | -133,675,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.82
Max Pain — expiry 2026-11-20
max pain strike: $20.00 · spot: $18.20 · call oi: 4,578 · put oi: 735
Expected Move to 2026-11-20:
±$3.90
(21.43%) —
implied range
$14.30 –
$22.10
· ATM straddle on $18.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | $1.63B | $33.91 | — |
| GHRS | GH Research PLC | $1.64B | $23.84 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.65B | $57.68 | — |
| STOK | Stoke Therapeutics, Inc. | $1.60B | $24.80 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.66B | $9.10 | — |
News headlines (Yahoo Finance, 1h cache)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-09-04 20:01 · Yahoo
Syndax Announces Participation in September Investor Conferences
2026-09-01 11:00 · Yahoo
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?
2026-08-12 21:35 · Yahoo
Syndax (SNDX) Q2 2026 Earnings Call Transcript
2026-08-12 02:45 · Yahoo
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors
2026-08-07 14:18 · Yahoo
Syndax Pharmaceuticals Q2 Earnings Call Highlights
2026-08-05 03:03 · Yahoo
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-04 20:01 · Yahoo
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
2026-07-28 11:00 · Yahoo
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
2026-07-14 20:02 · Yahoo
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
2026-07-14 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.